"Minimizing tacrolimus" strategy and long-term survival after liver transplantation

World Journal of Gastroenterology

Volumn 20, Issue 32, 2014, Pages 11363-11369

  Jia, Jun Jun ^a   Lin, Bin Yi ^a   He, Jiang Juan ^a   Geng, Lei ^a   Kadel, Dhruba ^a   Wang, Li ^a   Yu, Dong Dong ^a   Shen, Tian ^a   Yang, Zhe ^a   Ye, Yu Fu ^a   Zhou, Lin ^a   Zheng, Shu Sen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Immunosuppressive drug; Liver transplantation; Minimizing tacrolimus; Outcome; Tacrolimus

Indexed keywords

FLUCONAZOLE; GANCICLOVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; METHYLPREDNISOLONE; PIPERACILLIN PLUS TAZOBACTAM; TACROLIMUS; CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; DRUG EXPOSURE; DRUG MONITORING; DRUG SCREENING; FEMALE; FOLLOW UP; GRAFT REJECTION; HUMAN; INFECTION; KIDNEY FAILURE; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OUTCOME ASSESSMENT; PERSONAL EXPERIENCE; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR RECURRENCE; UNIVERSITY HOSPITAL; ADVERSE EFFECTS; CHI SQUARE DISTRIBUTION; CHINA; DRUG EFFECTS; GRAFT SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADULT; CALCINEURIN INHIBITORS; CHI-SQUARE DISTRIBUTION; CHINA; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84909584202     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i32.11363     Document Type: Article

References (26)

1. Varo Pérez E, Castroagudín JF. The future of liver transplantation. Transplant Proc 2010; 42: 613-616 [PMID: 20304206 DOI: 10.1016/j.transproceed.2010.02.003]
2. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med 1994; 331: 1110-1115 [PMID: 7523946 DOI: 10.1056/NEJM199410273311702]
3. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006; (4): CD005161 [PMID: 17054241 DOI: 10.1002/14651858.CD005161]
4. Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G, Scheller D, Ersfeld D, Frick M, Fitzsimmons WE, Virji M, Jain A, Brayman KL, Shaked A. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol 2001; 41: 542-551 [PMID: 11361051 DOI: 10.1177/00912700122010429]
5. Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol 2004; 57: 298-309 [PMID: 14998426 DOI: 10.1046/j.1365-2125.2003.02008.x]
6. Wiesner RH, Fung JJ. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl 2011; 17 Suppl 3: S1-S9 [PMID: 21850697 DOI: 10.1002/lt.22410]
7. Koesukwiwat U, Jayanta S, Leepipatpiboon N. Validation of a liquid chromatography-mass spectrometry multi-residue method for the simultaneous determination of sulfonamides, tetracyclines, and pyrimethamine in milk. J Chromatogr A 2007; 1140: 147-156 [PMID: 17187807 DOI: 10.1016/j.chroma.2006.11.099]
8. Ansermot N, Fathi M, Veuthey JL, Desmeules J, Hochstrasser D, Rudaz S. Quantification of cyclosporine A in peripheral blood mononuclear cells by liquid chromatography-electrospray mass spectrometry using a columnswitching approach. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 857: 92-99 [PMID: 17656161 DOI: 10.1016/j.jchromb.2007.07.001]
9. Crettol S, Venetz JP, Fontana M, Aubert JD, Ansermot N, Fathi M, Pascual M, Eap CB. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics 2008; 18: 307-315 [PMID: 18334915 DOI: 10.1097/FPC.0b013e3282f7046f]
10. Boillot O, Seket B, Dumortier J, Pittau G, Boucaud C, Bouffard Y, Scoazec JY. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study. Liver Transpl 2009; 15: 1426-1434 [PMID: 19877264 DOI: 10.1002/lt.21905]
11. Calmus Y, Kamar N, Gugenheim J, Duvoux C, Ducerf C, Wolf P, Samuel D, Vanlemmens C, Neau-Cransac M, Salamé E, Chazouillères O, Declerck N, Pageaux GP, Dubel L, Rostaing L. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. Transplantation 2010; 89: 1504-1510 [PMID: 20495510 DOI: 10.1097/TP.0b013e3181db8cf0]
12. Truneèka P, Boillot O, Seehofer D, Pinna AD, Fischer L, Ericzon BG, Troisi RI, Baccarani U, Ortiz de Urbina J, Wall W. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant 2010; 10: 2313-2323 [PMID: 20840481 DOI: 10.1111/j.1600-6143.2010.03255.x]
13. Boudjema K, Camus C, Saliba F, Calmus Y, Salamé E, Pageaux G, Ducerf C, Duvoux C, Mouchel C, Renault A, Compagnon P, Lorho R, Bellissant E. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant 2011; 11: 965-976 [PMID: 21466650 DOI: 10.1111/j.1600-6143.2011.03486.x]
14. Rodríguez-Perálvarez M, Germani G, Papastergiou V, Tsochatzis E, Thalassinos E, Luong TV, Rolando N, Dhillon AP, Patch D, O'Beirne J, Thorburn D, Burroughs AK. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. J Hepatol 2013; 58: 262-270 [PMID: 23023010 DOI: 10.1016/j.jhep.2012.09.019]
15. Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O'Beirne J, Poyato-González A, Ferrín-Sánchez G, Montero-Álvarez JL, Patch D, Thorburn D, Briceño J, De la Mata M, Burroughs AK. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013; 59: 1193-1199 [PMID: 23867318 DOI: 10.1016/j.jhep.2013.07.012]
16. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62: 920-926 [PMID: 8878385 DOI: 10.1097/00007890-199610150-00009]
17. Rodríguez-Perálvarez M, Germani G, Darius T, Lerut J, Tsochatzis E, Burroughs AK. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant 2012; 12: 2797-2814 [PMID: 22703529 DOI: 10.1111/j.1600-6143.2012.04140.x]
18. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940 [PMID: 12954741 DOI: 10.1056/NEJMoa021744]
19. Nashan B, Saliba F, Durand F, Barcéna R, Herrero JI, Mentha G, Neuhaus P, Bowles M, Patch D, Bernardos A, Klempnauer J, Bouw R, Ives J, Mamelok R, McKay D, Truman M, Marotta P. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. Liver Transpl 2009; 15: 136-147 [PMID: 19177449 DOI: 10.1002/lt.21657]
20. Karie-Guigues S, Janus N, Saliba F, Dumortier J, Duvoux C, Calmus Y, Lorho R, Deray G, Launay-Vacher V, Pageaux GP. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study. Liver Transpl 2009; 15: 1083-1091 [PMID: 19718632 DOI: 10.1002/lt.21803]
21. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989; 2: 1000-1004 [PMID: 2478846 DOI: 10.1016/S0140-6736(89)91014-3]
22. O'Grady JG, Hardy P, Burroughs AK, Elbourne D. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant 2007; 7: 137-141 [PMID: 17109723 DOI: 10.1111/j.1600-6143.2006.01576.x]
23. Pollock-Barziv SM, Finkelstein Y, Manlhiot C, Dipchand AI, Hebert D, Ng VL, Solomon M, McCrindle BW, Grant D. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr Transplant 2010; 14: 968-975 [PMID: 21040278 DOI: 10.1111/j.1399-3046.2010.01409.x]
24. Capron A, Lerut J, Latinne D, Rahier J, Haufroid V, Wallemacq P. Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study. Transpl Int 2012; 25: 41-47 [PMID: 21981711 DOI: 10.1111/j.1432-2277.2011.01365.x]
25. Barbier L, Garcia S, Cros J, Borentain P, Botta-Fridlund D, Paradis V, Le Treut YP, Hardwigsen J. Assessment of chronic rejection in liver graft recipients receiving immunosuppression with low-dose calcineurin inhibitors. J Hepatol 2013; 59: 1223-1230 [PMID: 23933266 DOI: 10.1016/j.jhep.2013.07.032]
26. Uesugi M, Hosokawa M, Shinke H, Hashimoto E, Takahashi T, Kawai T, Matsubara K, Ogawa K, Fujimoto Y, Okamoto S, Kaido T, Uemoto S, Masuda S. Influence of cytochrome P450 (CYP) 3A4∗1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients. Biol Pharm Bull 2013; 36: 1814-1821 [PMID: 24189425 DOI: 10.1248/bpb.b13-00509]